Privi Speciality Chemicals Ltd Q2 FY2025 Concall Summary

Key Takeaways

• Record quarter, volume-led: Revenue crossed Rs. 500 crores for the first time on record volume of 11,504 metric tons, though lower realizations from yearly contracts kept turnover growth at 16-17% against 33% volume growth.
• Givaudan JV is live and derisked: The greenfield plant has been inaugurated, water trials are underway, and all 42 specialty products are pre-committed to Givaudan under a 51:49 Privi-majority structure.
• Margins hit a sustainable 21%+: EBITDA margin reached 21.1% in H1, up from 17.9% a year ago, and management says this level is sustainable and should only improve as value-added products and higher volumes spread factory costs.
• Pricing cycle is turning: Spot prices have started moving up and 2025 contracts are being signed at better prices, though current realizations remain 25% below FY22/FY23 peaks because 2024 contracts were locked when raw material prices were low.
• What to watch next quarter: Whether the promised H2 uplift materializes, the pace of JV ramp-up and specialty product optimization, and any concrete announcement on the QIP, acquisition or Furfural project timelines.

The Givaudan Joint Venture

• Structure and scale: Privi holds 51%, Givaudan 49%. The JV will manufacture 42 specialty products transferred from Givaudan's 80-year-old manufacturing base, supplied exclusively to Givaudan. Management expects topline to start around Rs. 150 crores and double over coming years as capacity expands.
• Operational status: The plant was inaugurated in October and water trials are ongoing. Optimization of the specialty products will take about two years, with a progressive ramp-up in activities over that period. No hiccups reported so far.
• Strategic significance: The deal positions Privi as a technology partner to a Global Fortune 500 company, with the Indian partner holding majority control. Management declined to disclose whether the ~24% EBITDA margin expectation is contractually embedded, calling the arrangement confidential.

Rajan: "The first thing is that we should be proud that as Indians, Global Fortune 500 giant has relied on us to be their technology partners with Privi having 51% and they having 49% and they have Speciality products which they have been manufacturing for nearly 80 years."

Volume, Realization & the Pricing Cycle

• The volume-value gap: Volume grew 33% YoY but revenue grew only 16-17% because 2024 yearly contracts were signed in late 2023 when raw material prices were depressed, locking in lower realizations. Spot prices are now improving and 2025 contracts are being signed at better prices.
• Realization trajectory: Realizations improved 7% QoQ in Q2, but remain roughly 25% below the peaks of FY22/FY23. Management is cautiously optimistic that the pricing environment is turning.
• Gross margin resilience: Despite price swings, gross profit per ton has stabilized around Rs. 2 lakhs over the last 3-4 years because value-added products and yield improvements have sustained margins at the gross level. EBITDA margin improvement to 20%+ over the last six quarters reflects the same value-added shift plus factory overhead spread over higher volumes.
• Volume as a misleading metric: Management cautioned that volume alone can mislead: selling 20 tons at \$55 is better than 100 tons at \$2. Gross margin is the key metric to track.

Product & Capacity Expansion

• Prionyl scale-up: The Prionyl process has seen success; capacity is being augmented four-fold to 150 tons per annum, and current production is already pre-sold. Management called it "the Holy Grail of aroma chemicals."
• Camphor upgrade: Camphor is now listed with the US-FDA as an ingredient for formulation, opening a pharma-grade market where realizations are expected to be 25-40% higher than industrial grade. Several large pharma customers had requested this listing.
• Indomeran ambition: Capacity will be expanded significantly within this year, with the stated goal of becoming one of the largest manufacturers of Indomeran globally.
• New specialty launch: A specialty product priced at \$300+ was launched in recent months; market feedback is being gathered.
• Pipeline depth: The company has evolved from 2 products to 72+, with 42 for the JV and 20+ in the R&D pipeline. R&D facilities at Mahad and Navi Mumbai are DSIR-recognized.

Babani: "Indomeran is going to be our star product, and we are hoping to be I told you in short, one of the largest."

Margins & Cost Structure

• H1 margin delivery: EBITDA reached Rs. 212 crores on total income of Rs. 1,004 crores, a 35% increase in absolute EBITDA and a margin expansion to 21.1% from 17.9% a year ago.
• Sustainability claim: Management stated that 21%+ EBITDA margins are sustainable and should only improve from here, driven by value-added products, continuous-plant capacity additions within existing infrastructure, and operating leverage on rising volumes.
• Cost headwinds: Selling and distribution expenses rose with higher sales volumes and export share. The Iran-Israel dispute increased freight costs, affecting all exporters. Other expenses were otherwise under control.
• Gross margin outlook: Management expects raw material cost as a percentage of sales to improve a little, or at minimum be maintained at current levels.

Balance Sheet, CAPEX & Capital Allocation

• Near-term CAPEX: Rs. 200-250 crores planned over the next one year, directed at capacity increases for key Pine-space products (Dihydromyrcenol, Amber Fleur, Pine Oil) and potentially Galaxmusk.
• Longer-term capacity target: With QIP proceeds, new products will be introduced and the company targets reaching approximately 60,000 metric tons of total capacity.
• Debt position: Term loan repayment is proceeding on schedule and all bank obligations have been repaid. Management did not answer a specific question on whether debt-to-EBITDA will fall below 2x this year.
• QIP and acquisition timelines: Both the QIP and a previously announced acquisition remain at the "bankers will inform at the appropriate time" stage. Management requested investors restrict questions on acquisitions, citing prudent governance policy.
• Furfural project: A new building-block project, claimed to be the first of its kind in India, may take longer: "maybe this year, maybe next year, within next 2-3 years for sure."

Demand Environment & Growth Outlook

• End-market demand: Customer turnover is up 10%, with India, Brazil and Indonesia growing. Structural drivers include rising women's workforce participation in India boosting perfume and cosmetic consumption, Oriental and Woody notes gaining global favor, and post-COVID hygiene trends persisting.
• Volume growth expectation: 20% volume growth expected over the next 15-18 months.
• H2 seasonality: Historically, the second half is 20% higher than the first half; management expects better results in H2 FY25.
• Strategic alliance pipeline: Management expects 1-2 more tie-ups similar to the Givaudan JV in the next 2-3 years, though future arrangements may be strategic alliances with exclusivity and confidentiality rather than equity JVs.

Babani: "we will maintain, like you see, a CAGR is almost 19% for last 20 years and we will be able to maintain this or improve this further in the next few years. That is the way of life, to be honest."

Guidance & Commitments

Key Metrics